Cooley Advises Otsuka on its $825 Million Collaboration Agreement to Develop Alzheimer's Drug

Palo Alto, Calif. – March 29, 2013 – Cooley LLP announced today that it advised Otsuka in its $825 million collaboration agreement with Lundbeck to further the development and commercialization of a developmental drug, Lu AE58054, for the treatment of Alzheimer's disease.

Under the terms of the agreement, Lundbeck will receive an initial payment of $150 million and both companies will share the sales, development, and commercialization costs. In exchange, Lundbeck will grant Otsuka co-development and co-commercialization rights to Lu AE58054 in the US, Canada, East Asia, including Japan, and in major European and Nordic countries.

Otsuka is a global healthcare company that researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health. Lundbeck is a global pharmaceutical company committed to improving the quality of life of people living with brain diseases.

The Cooley team that advised Otsuka was led by Seattle-based of counsel, Alison Freeman-Gleason and Palo Alto-based partner Lila Hope and included Washington, DC-based partner Thomas Blinka.

About Cooley LLP

Cooley's 700 attorneys have an entrepreneurial spirit and deep, substantive experience, and are committed to solving clients' most challenging legal matters. From small companies with big ideas to international enterprises with diverse legal needs, Cooley has the breadth of legal resources to enable companies of all sizes to seize opportunities in today's global marketplace. The firm represents clients across a broad array of dynamic industry sectors, including technology, life sciences, venture capital, clean energy, real estate and retail.

The firm has full-service offices in eleven major business and technology centers: Boston, MA; Broomfield, CO; Los Angeles, CA; New York, NY; Palo Alto, CA; Reston, VA; San Diego, CA; San Francisco, CA; Seattle, WA; Washington, DC; and Shanghai, China.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.